The secretary of the board of directors of Dongya Pharmaceutical replied: Rheumatoid arthritis drugs are one of the key research and development directions of the company

On January 20, Dongya Pharmaceutical (605177) answered investors' concerns on the investor relations platform.

Investor: Please ask if your company has any production. dexamethasone. Artemisinin hydroxychloroquine...

Secretary of the Board of Directors of Dongya Pharmaceutical: Hello! Thanks to the attention, the company does not produce dexamethasone and artemisinin hydroxychloroquine.

Investors: On January 14, the WHO issued an announcement on the 14th local time, recommending that baritinib (baricitinib) be combined with corticosteroids to treat patients with severe covid-19. There is evidence that it can improve patient survival and reduce the need for ventilators, and no increase in adverse reactions has been observed. What stage has your baretinib products reached?

Secretary of the Board of Directors of Dongya Pharmaceutical: Hello! Thank you for your attention, rheumatoid arthritis drugs are one of the company's key research and development directions, barritinib, tofatinib, fenofitinib, etc. are suitable for rheumatoid arthritis diseases, the company has set up a project for research and development, but as of now are still in the development stage, whether it can be successfully developed has an uncertain risk, please pay attention to the risk of investors.

Investors: WHO today issued an announcement recommending the treatment of severe COVID-19 patients by combining barretinib with cortisterol. There is evidence that it can improve patient survival and reduce the need for ventilators, and no increase in adverse reactions has been observed. Does your company have barritinib products or related production technologies?

Investor: How is the company's baritinib research and development progress? WHO has listed it as a cure for COVID-19, and companies should step up their research and development efforts.

According to the 2021 third quarter report of Dongya Pharmaceutical, the company's main revenue was 472 million yuan, down 30.26% year-on-year; the net profit attributable to the mother was 53.3528 million yuan, down 50.46% year-on-year; the deduction of non-net profit was 35.4609 million yuan, down 64.59% year-on-year; among them, in the third quarter of 2021, the company's single-quarter main revenue was 127 million yuan, down 25.38% year-on-year; the single-quarter net profit attributable to the mother was -4.7652 million yuan, down 122.03% year-on-year. Single-quarter deduction of non-net profit - 8.7217 million yuan, down 162.32% year-on-year; debt ratio of 21.61%, investment income of 4.7389 million yuan, financial expenses - 15.5217 million yuan, gross profit margin of 30.82%.

The unit has not had an institutional rating in the last 90 days. The Securities Star Valuation Analysis Tool shows that Bea Pharmaceutical (605177) has a good company rating of 2.5 stars, a good price rating of 1.5 stars, and a comprehensive valuation rating of 2 stars. (Rating Range: 1 ~ 5 stars, maximum 5 stars)

The main business of Dongya Pharmaceutical: research and development, production and sales of chemical RAW materials and pharmaceutical intermediates

The chairman of the company is Chi Zhengming. Mr. Chi Zhengming: Born in September 1957, Chinese nationality, with Australian permanent residency, college degree, senior economist, engineer, has worked in Zhejiang Huangyan Chemical Industry Co., Ltd., Zhejiang Huangyan First Chemical Factory, Shanghai Chengjiang Chemical Co., Ltd., Zhejiang Huangyan Fengrun Plastic Factory, Shanghai Ouhu Pharmaceutical Technology Co., Ltd. and other companies. From June 1995 to June 2015, he served as the chairman and general manager of Zhejiang Dongya Pharmaceutical & Chemical Co., Ltd.; From October 2000 to May 2004, he served as the chairman of Shanghai Pukang Pharmaceutical Co., Ltd.; From October 2002 to July 2007, he served as the legal representative of Zhejiang Sanmen Dongya Pharmaceutical Co., Ltd.; From May 2004 to July 2018, he served as the vice chairman of Shanghai Pukang Pharmaceutical Co., Ltd.; From October 2005 to July 2015, he served as the person in charge and legal representative of Huangyan Fengrun Plastic Factory; From June 2006 to December 2015, he served as the executive director and general manager of Zhejiang Dongya Medical Chemical Import and Export Co., Ltd.; He was the general manager of Zhejiang Dongya Pharmaceutical Co., Ltd. Since February 1998, he has served as the chairman and general manager of the company; Since August 2004, he has served as the chairman and manager of Zhejiang Dongbang Pharmaceutical Co., Ltd.; Since July 2005, he has been the vice chairman of Zhejiang Jinming Pharmaceutical Co., Ltd.; Since January 2006, he has been the executive director of Shanghai Right Hand Pharmaceutical Technology Development Co., Ltd. Since December 21, 2018, he has been the executive director of Sanmen Bangya Crafts Co., Ltd.

This article is compiled by the Securities Star Data Center based on publicly available data and does not constitute investment opinions or suggestions, if you have any questions, please contact us.